TrialThe oncologist2021

A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer.

Bora Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.